Möchten Sie über diese Zeitschrift informiert bleiben? Klicken Sie bitte auf die Buttons, um unsere Alerts zu abonnieren.
Möchten Sie über diese Zeitschrift informiert bleiben? Klicken Sie bitte auf die Buttons, um unsere Alerts zu abonnieren.
Production of human elafin by genetically modified Lactococcus lactis: evaluation of its anti-inflammatory effects in a murine model of intestinal mucositis
in Beneficial MicrobesSearch for other papers by R. Levit in
Current site
Google Scholar
Search for other papers by A. de Moreno de LeBlanc in
Current site
Google Scholar
Search for other papers by S. Gontier in
Current site
Google Scholar
Search for other papers by A. Aucouturier in
Current site
Google Scholar
Search for other papers by P. Langella in
Current site
Google Scholar
Search for other papers by L.G. Bermúdez-Humarán in
Current site
Google Scholar
Search for other papers by J.G. LeBlanc in
Current site
Google Scholar
Abstract
The aim of this study was to develop a recombinant strain of Lactococcus lactis designed to produce human elafin, a serine protease inhibitor, through a Stress-Inducible Controlled Expression (SICE) System, and to evaluate its anti-inflammatory potential both in vitro and in vivo. The impact of this recombinant strain on the efficacy of 5-Fluorouracil (5-FU) was evaluated by in vitro assays with Caco-2 (human colonic cancer cells) and IEC-18 (non-cancerous intestinal cells) exposed to 5-FU with or without the recombinant bacterium. In vivo, a mouse model of intestinal mucositis (IM) was induced by daily injections of 5-FU, followed by oral administration of the recombinant strain twice daily. Key assessments included the occurrence of diarrhea, small intestinal morphology and histopathology, and serum cytokines levels. In vitro results showed that the elafin-producing strain enhanced 5-FU cytotoxicity against Caco-2 cells, while preserving IEC-18 cell viability in the presence of 5-FU. In vivo, the strain significantly reduced the occurrence of diarrhea, improved the villus height/crypt depth ratio and attenuated intestinal inflammation. In addition, the recombinant strain reduced serum levels of the pro-inflammatory cytokines IL-6 and TNF-α, while significantly increasing the anti-inflammatory cytokine IL-10. Importantly, the strain did not compromise the anti-cancer efficacy of 5-FU on tumor cells and protected non-cancer cells. These results confirm the in vivo anti-inflammatory effects of this elafin-producing strain against IM.
Kauf
Sofortzugang erwerben (PDF-Download und unbegrenzter Online-Zugang):
Institutszugang
Melden Sie sich mit Open Athens, Shibboleth oder Ihren institutionellen Anmeldedaten an.
Persönliche Anmeldung
Melden Sie sich mit Ihrem brill.com-Konto an
-
Avci, G.A., Yilmaz, Ü.İ. and Avci, E., 2024. Efficacy of probiotics, paraprobiotics, and postbiotics in colorectal cancer cell line and their role in immune response. Revista da Associação Médica Brasileira 70(6): e20240226. https://doi.org/10.1590/1806-9282.20240226
-
Benbouziane, B., Ribelles, P., Aubry, C., Martin, R., Kharrat, P., Riazi, A., Langella, P. and Bermudez-Humaran, L.G., 2013. Development of a Stress-Inducible Controlled Expression (SICE) system in Lactococcus lactis for the production and delivery of therapeutic molecules at mucosal surfaces. Journal of Biotechnology 168: 120-129. https://doi.org/10.1016/j.jbiotec.2013.04.019
-
Bermúdez-Humarán, L.G., Motta, J.-P., Aubry, C., Kharrat, P., Rous-Martin, L., Sallenave, J.-M., Deraison, C., Vergnolle, N. and Langella, P., 2015. Serine protease inhibitors protect better than IL-10 and TGF-β anti-inflammatory cytokines against mouse colitis when delivered by recombinant lactococci. Microbial Cell Factories 14: 1-11. https://doi.org/10.1186/s12934-015-0198-4
-
Carvalho, R.D., Breyner, N., Menezes-Garcia, Z., Rodrigues, N.M., Lemos, L., Maioli, T.U., da Gloria Souza, D., Carmona, D., de Faria, A. and Langella, P., 2017. Secretion of biologically active pancreatitis-associated protein I (PAP) by genetically modified dairy Lactococcus lactis NZ9000 in the prevention of intestinal mucositis. Microbial Cell Factories 16: 1-11. https://doi.org/10.1186/s12934-017-0624-x
-
Cook, D.P., Gysemans, C. and Mathieu, C., 2018. Lactococcus lactis as a versatile vehicle for tolerogenic immunotherapy. Frontiers in Immunology 8: 1961. https://doi.org/10.3389/fimmu.2017.01961
-
Daniel, C., Poiret, S., Dennin, V., Boutillier, D. and Pot, B., 2013. Bioluminescence imaging study of spatial and temporal persistence of Lactobacillus plantarum and Lactococcus lactis in living mice. Applied and Environmental Microbiology 79(4): 1086-1094. https://doi.org/10.1128/AEM.03221-12
-
Deraison, C., Bonnart, C., Langella, P., Roget, K. and Vergnolle, N., 2023. Elafin and its precursor trappin-2: what is their therapeutic potential for intestinal diseases? British Journal of Pharmacology 180: 144-160. https://doi.org/10.1111/bph.15985
-
Derissen, E.J. and Beijnen, J.H., 2020. Intracellular pharmacokinetics of pyrimidine analogues used in oncology and the correlation with drug action. Clinical Pharmacokinetics 59: 1521-1550. https://doi.org/10.1007/s40262-020-00934-7
-
Galipeau, H.J., Wiepjes, M., Motta, J.-P., Schulz, J.D., Jury, J., Natividad, J.M., Pinto-Sanchez, I., Sinclair, D., Rousset, P. and Martin-Rosique, R.A., 2014. Novel role of the serine protease inhibitor elafin in gluten-related disorders. Official Journal of the American College of Gastroenterology 109: 748-756. https://doi.org/10.1038/ajg.2014.48
-
Huang, L., Chiau, J.-S.C., Cheng, M.-L., Chan, W.-T., Jiang, C.-B., Chang, S.-W., Yeung, C.-Y. and Lee, H.-C., 2019. SCID/NOD mice model for 5-FU induced intestinal mucositis: safety and effects of probiotics as therapy. Pediatrics and Neonatology 60: 252-260. https://doi.org/10.1016/j.pedneo.2018.07.007
-
Huang, T.-Y., Chu, H.-C., Lin, Y.-L., Ho, W.-H., Hou, H.-S., Chao, Y.-C. and Liao, C.-L., 2009. Minocycline attenuates 5-fluorouracil-induced small intestinal mucositis in mouse model. Biochemical and Biophysical Research Communications 389: 634-639. https://doi.org/10.1016/j.bbrc.2009.09.041
-
Justino, P.F., Melo, L.F., Nogueira, A.F., Costa, J.V., Silva, L.M., Santos, C.M., Mendes, W.O., Costa, M.R., Franco, A.X. and Lima, A.A., 2014. Treatment with Saccharomyces boulardii reduces the inflammation and dysfunction of the gastrointestinal tract in 5-fluorouracil-induced intestinal mucositis in mice. British Journal of Nutrition 111: 1611-1621. https://doi.org/10.1017/S0007114513004248
-
Kok, J., Van der Vossen, J.M. and Venema, G., 1984. Construction of plasmid cloning vectors for lactic streptococci which also replicate in Bacillus subtilis and Escherichia coli. Applied and Environmental Microbiology 48(4): 726-731. https://doi.org/10.1128/aem.48.4.726-731.1984
-
Levit, R., Cortes-Perez, N.G., de Moreno de Leblanc, A., Loiseau, J., Aucouturier, A., Langella, P., LeBlanc, J.G. and Bermúdez-Humarán, L.G., 2022. Use of genetically modified lactic acid bacteria and bifidobacteria as live delivery vectors for human and animal health. Gut Microbes 14: 2110821. https://doi.org/10.1080/19490976.2022.2110821
-
Levit, R., Savoy de Giori, G., de Moreno de LeBlanc, A. and LeBlanc, J.G., 2018a. Folate-producing lactic acid bacteria reduce inflammation in mice with induced intestinal mucositis. Journal of Applied Microbiology 125: 1494-1501. https://doi.org/10.1111/jam.14038
-
Levit, R., Savoy de Giori, G., de Moreno de LeBlanc, A. and LeBlanc, J.G., 2018b. Protective effect of the riboflavin-overproducing strain Lactobacillus plantarum CRL2130 on intestinal mucositis in mice. Nutrition 54: 165-172. https://doi.org/10.1016/j.nut.2018.03.056
-
Lu, K., Dong, S., Wu, X., Jin, R. and Chen, H., 2021. Probiotics in cancer. Frontiers in Oncology 11: 638148. https://doi.org/10.3389/fonc.2021.638148
-
Martı́n, R., Chain, F., Miquel, S., Natividad, J.M. and Sokol, H., 2014. Effects in the use of a genetically engineered strain of Lactococcus lactis delivering in situ IL-10 as a therapy to treat low-grade colon inflammation. Human Vaccines & Immunotherapeutics 10: 1611-1621. https://doi.org/10.4161/hv.28549
-
Miknevicius, P., Zulpaite, R., Leber, B., Strupas, K., Stiegler, P. and Schemmer, P., 2021. The impact of probiotics on intestinal mucositis during chemotherapy for colorectal cancer: a comprehensive review of animal studies. International Journal of Molecular Sciences 22(17): 9347. https://doi.org/10.3390/ijms22179347
-
Morello, E., Bermudez-Humaran, L., Llull, D., Sole, V., Miraglio, N., Langella, P. and Poquet, I., 2008. Lactococcus lactis, an efficient cell factory for recombinant protein production and secretion. Journal of Molecular Microbiology and Biotechnology 14: 48-58. https://doi.org/10.1159/000106082
-
Motta, J.-P., Bermúdez-Humarán, L.G., Deraison, C., Martin, L., Rolland, C., Rousset, P., Boue, J., Dietrich, G., Chapman, K. and Kharrat, P., 2012. Food-grade bacteria expressing elafin protect against inflammation and restore colon homeostasis. Science Translational Medicine 4: 158ra144-158ra144. https://doi.org/10.1126/scitranslmed.3004212
-
Poquet, I., Ehrlich, S.D. and Gruss, A., 1998. An export-specific reporter designed for gram-positive bacteria: application to Lactococcus lactis. Journal of Bacteriology 180(7): 1904-1912. https://doi.org/10.1128/jb.180.7.1904-1912.1998
-
Quaresma, M., Damasceno, S., Monteiro, C., Lima, F., Mendes, T., Lima, M., Justino, P., Barbosa, A., Souza, M. and Souza, E., 2020. Probiotic mixture containing Lactobacillus spp. and Bifidobacterium spp. attenuates 5-fluorouracil-induced intestinal mucositis in mice. Nutrition and Cancer 72: 1355-1365. https://doi.org/10.1080/01635581.2019.1675719
-
Ribeiro, R.A., Wanderley, C.W.S., Wong, D.V.T., Mota, J.M.S.C., Leite, C.A.V.G., Souza, M.H.L.P., Cunha, F.Q. and Lima-Júnior, R.C.P., 2016. Irinotecan-and 5-fluorouracil-induced intestinal mucositis: insights into pathogenesis and therapeutic perspectives. Cancer Chemotherapy and Pharmacology 78: 881-893. https://doi.org/10.1007/s00280-016-3139-y
-
Sadiq, M.B., 2022. Lactic acid bacteria as potential probiotics. In: Panesar, P.S. and Anal, A.K. (eds.) Probiotics, prebiotics and synbiotics: technological advancements towards safety and industrial applications. John Wiley & Sons Ltd. Publisher, Hoboken, New Jersey, USA, pp. 57-72. https://doi.org/10.1002/9781119702160.ch3
-
Shaw, L. and Wiedow, O., 2011. Therapeutic potential of human elafin. Biochemical Society Transactions 39: 1450-1454. https://doi.org/10.1042/BST0391450
-
Shen, S.-R., Chen, W.-J., Chu, H.-F., Wu, S.-H., Wang, Y.-R. and Shen, T.-L., 2021. Amelioration of 5-fluorouracil-induced intestinal mucositis by Streptococcus thermophilus ST4 in a mouse model. PLoS ONE 16: e0253540. https://doi.org/10.1371/journal.pone.0253540
-
Sougiannis, A.T., VanderVeen, B.N., Davis, J.M., Fan, D. and Murphy, E.A., 2021. Understanding chemotherapy-induced intestinal mucositis and strategies to improve gut resilience. American Journal of Physiology: Gastrointestinal and Liver Physiology 320: G712-G719. https://doi.org/10.1152/ajpgi.00380.2020
-
Tavares, L.M., De Jesus, L.C.L., Da Silva, T.F., Barroso, F.A.L., Batista, V.L., Coelho-Rocha, N.D., Azevedo, V., Drumond, M.M. and Mancha-Agresti, P., 2020. Novel strategies for efficient production and delivery of live biotherapeutics and biotechnological uses of Lactococcus lactis: the lactic acid bacterium model. Frontiers in Bioengineering and Biotechnology 8: 1269. https://doi.org/10.3389/fbioe.2020.517166
-
Yeung, C.-Y., Chan, W.-T., Jiang, C.-B., Cheng, M.-L., Liu, C.-Y., Chang, S.-W., Chiau, J.-S.C. and Lee, H.-C., 2015. Amelioration of chemotherapy-induced intestinal mucositis by orally administered probiotics in a mouse model. PLoS ONE 10: e0138746. https://doi.org/10.1371/journal.pone.0138746
| Insgesamt | Letzte 365 Tage | In den letzten 30 Tagen | |
|---|---|---|---|
| Aufrufe von Kurzbeschreibungen | 705 | 363 | 10 |
| Gesamttextansichten | 17 | 10 | 0 |
| PDF-Downloads | 43 | 29 | 0 |
Production of human elafin by genetically modified Lactococcus lactis: evaluation of its anti-inflammatory effects in a murine model of intestinal mucositis
in Beneficial MicrobesSearch for other papers by R. Levit in
Current site
Google Scholar
PubMed
Search for other papers by A. de Moreno de LeBlanc in
Current site
Google Scholar
PubMed
Search for other papers by S. Gontier in
Current site
Google Scholar
PubMed
Search for other papers by A. Aucouturier in
Current site
Google Scholar
PubMed
Search for other papers by P. Langella in
Current site
Google Scholar
PubMed
Search for other papers by L.G. Bermúdez-Humarán in
Current site
Google Scholar
PubMed
Search for other papers by J.G. LeBlanc in
Current site
Google Scholar
PubMed
Abstract
The aim of this study was to develop a recombinant strain of Lactococcus lactis designed to produce human elafin, a serine protease inhibitor, through a Stress-Inducible Controlled Expression (SICE) System, and to evaluate its anti-inflammatory potential both in vitro and in vivo. The impact of this recombinant strain on the efficacy of 5-Fluorouracil (5-FU) was evaluated by in vitro assays with Caco-2 (human colonic cancer cells) and IEC-18 (non-cancerous intestinal cells) exposed to 5-FU with or without the recombinant bacterium. In vivo, a mouse model of intestinal mucositis (IM) was induced by daily injections of 5-FU, followed by oral administration of the recombinant strain twice daily. Key assessments included the occurrence of diarrhea, small intestinal morphology and histopathology, and serum cytokines levels. In vitro results showed that the elafin-producing strain enhanced 5-FU cytotoxicity against Caco-2 cells, while preserving IEC-18 cell viability in the presence of 5-FU. In vivo, the strain significantly reduced the occurrence of diarrhea, improved the villus height/crypt depth ratio and attenuated intestinal inflammation. In addition, the recombinant strain reduced serum levels of the pro-inflammatory cytokines IL-6 and TNF-α, while significantly increasing the anti-inflammatory cytokine IL-10. Importantly, the strain did not compromise the anti-cancer efficacy of 5-FU on tumor cells and protected non-cancer cells. These results confirm the in vivo anti-inflammatory effects of this elafin-producing strain against IM.
| Insgesamt | Letzte 365 Tage | In den letzten 30 Tagen | |
|---|---|---|---|
| Aufrufe von Kurzbeschreibungen | 705 | 363 | 10 |
| Gesamttextansichten | 17 | 10 | 0 |
| PDF-Downloads | 43 | 29 | 0 |
